close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

2.250 -0.080 (-3.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
Via ACCESS Newswire
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Via ACCESS Newswire
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Via ACCESS Newswire
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Via ACCESS Newswire
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Via ACCESS Newswire
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Via ACCESS Newswire
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Via ACCESS Newswire
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Via ACCESS Newswire
Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment
Via ACCESS Newswire
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Via ACCESS Newswire
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
Via ACCESS Newswire
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Via ACCESS Newswire
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR
Via ACCESS Newswire
Ensysce Biosciences Issues Annual Shareholder Letter
Via ACCESSWIRE
Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product
Via ACCESSWIRE
Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR
Via ACCESSWIRE
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Via ACCESS Newswire
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Via ACCESS Newswire
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial
Via ACCESSWIRE
Ensysce Biosciences Reports Third Quarter 2024 Financial Results
Via ACCESSWIRE
Ensysce Biosciences Announces Leadership Team’s Participation in the Annual Pain Therapeutics Summit
Via ACCESSWIRE
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Via ACCESS Newswire
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference
Via ACCESS Newswire
Ensysce Biosciences Regains Full Compliance with Nasdaq
Via ACCESSWIRE
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
Via ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today